Increased Competition for Big Pharma in Late-Stage Licensing?
Do in-licensing-focused specialty pharmas spell tougher competition for Big Pharma, traditionally the biggest customer for late-stage product licenses?
You may also be interested in...
A closer look at the trend in biotech (top tier, and others) and specialty pharma in-licensing of clinical stage products.
The European Medicines Agency commits to exploring real-world data as part of its new Regulatory Science Strategy to 2025.